Autopsy report · NCT00744653

Electrochemotherapy for Chest Wall Recurrence af Breast Cancer: Present Challenges and Future Prospects.

“Primary endpoint measure not suitable for evaluation”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 2 years 2 months before it stopped.
• 17 participants enrolled.
• Results were posted on the registry 3 years 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Copenhagen University Hospital at Herlev

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

Electrochemotherapy

Participants

17

Sites

1

Countries

Denmark

Trials that died the same way

• Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)
  “Primary endpoint not achieved” (75% match in meaning)
• PleuraSeal Pivotal Study (US)
  “Interim analysis results were not supportive of primary endpoint” (72% match in meaning)
• CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
  “Primary Endpoint not met” (72% match in meaning)
• A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
  “At the time of the primary analysis, results did not meet the primary endpoint” (72% match in meaning)
• Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer
  “primary endpoint was not met” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.